Neurocrine Biosciences (NASDAQ:NBIX) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Insider & Institutional Ownership
95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.2% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Neurocrine Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Profitability
This table compares Neurocrine Biosciences and NanoString Technologies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Neurocrine Biosciences | 8.96% | 18.18% | 9.50% |
NanoString Technologies | -53.47% | -68.96% | -24.15% |
Valuation & Earnings
This table compares Neurocrine Biosciences and NanoString Technologies' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Neurocrine Biosciences | $788.10 million | 13.05 | $37.01 million | $0.39 | 280.77 |
NanoString Technologies | $125.57 million | 26.14 | $-40,700,000.00 | ($1.93) | -38.60 |
Neurocrine Biosciences has higher revenue and earnings than NanoString Technologies. NanoString Technologies is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Neurocrine Biosciences and NanoString Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Neurocrine Biosciences | 0 | 8 | 11 | 0 | 2.58 |
NanoString Technologies | 0 | 1 | 4 | 0 | 2.80 |
Neurocrine Biosciences currently has a consensus price target of $129.2222, indicating a potential upside of 18.40%. NanoString Technologies has a consensus price target of $55.8333, indicating a potential downside of 24.89%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than NanoString Technologies.
Summary
Neurocrine Biosciences beats NanoString Technologies on 10 of the 14 factors compared between the two stocks.